Van Vugt 2002.

Methods	Randomized controlled trial Length of follow up: 42 d Generation of allocation sequence: block randomization Allocation concealment: sealed envelopes Blinding: none Inclusion of all randomized participants in the final analysis: 1063 analysed/1063 randomized (100%)
Participants	Number enrolled:1063 Age range: 2 to 70 years Gender: male and female Inclusion criteria: age 2 to 70 years; slide confirmed acute uncomplicated falciparum malaria; weight > 10 kg; written informed consent by patient or guardian; not pregnant; not received mefloquine in the previous 63 d; not obtunded; not vomiting; no other clinical or laboratory signs of severe illness Exclusion criteria: severe malaria; presence of mixed infections with other Plasmodium species; presence of concomitant disease (intercurrent febrile infections); 2‐week history of antimalarial administration; pregnancy; breastfeeding mother
Interventions	1. Atovaquone plus proguanil (atovaquone 15 mg/kg/d, proguanil 8 mg/kg/d for 3 d) 2. Artesunate plus mefloquine (artesunate 4 mg/kg/d for 3 d; mefloquine 15 mg/kg on day 1 and 10 mg/kg on day 2) Participants with axillary temperature > 38 °C given antipyretics and cooled by tepid sponging before drug administration
Outcomes	1. Incidence of microscopically and genetically confirmed recrudescent infections 2. Parasite clearance time 3. Fever clearance time 4. Adverse events 5. Degree of anaemia
Notes	Location: Thailand Drug resistance: multiple‐drug resistance except artemisinin derivatives